Mélanie Saville

11.2k total citations · 4 hit papers
44 papers, 5.7k citations indexed

About

Mélanie Saville is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mélanie Saville has authored 44 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 15 papers in Epidemiology and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mélanie Saville's work include Mosquito-borne diseases and control (14 papers), Influenza Virus Research Studies (13 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Mélanie Saville is often cited by papers focused on Mosquito-borne diseases and control (14 papers), Influenza Virus Research Studies (13 papers) and SARS-CoV-2 and COVID-19 Research (12 papers). Mélanie Saville collaborates with scholars based in France, United States and United Kingdom. Mélanie Saville's co-authors include Richard Hatchett, Nicole Lurie, Jane Halton, Raúl Gómez Román, Arun Kumar, Zacharias Andreadakis, Tung Thanh Le, Stephen Mayhew, Stig Tollefsen and Jean Lang and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Mélanie Saville

44 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The COVID-19 vaccine development landscape

2020 1.3k citations Arun Kumar, Raúl Gómez Román et al. profile →
Developing Covid-19 Vaccines at Pandemic Speed

2020 1.0k citations Nicole Lurie, Mélanie Saville et al. profile →
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

2012 636 citations Arunee Sabchareon, Derek Wallace et al. The Lancet profile →
Vaccine development for emerging infectious diseases

2021 256 citations Jean‐Louis Excler, Mélanie Saville et al. Nature Medicine profile →

Peers

Countries citing papers authored by Mélanie Saville

Since Specialization

Citations

This map shows the geographic impact of Mélanie Saville's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mélanie Saville with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mélanie Saville more than expected).

Fields of papers citing papers by Mélanie Saville

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mélanie Saville. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mélanie Saville. The network helps show where Mélanie Saville may publish in the future.

Co-authorship network of co-authors of Mélanie Saville

This figure shows the co-authorship network connecting the top 25 collaborators of Mélanie Saville. A scholar is included among the top collaborators of Mélanie Saville based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mélanie Saville. Mélanie Saville is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Standing the test of COVID-19: charting the new frontiers of medicine 2024 ·SHILAP Revista de lepidopterología ·Simon Cauchemez, Giulio Cossu, Nathalie M. Delzenne, Eran Elinav, Didier Fassin, Alain Fischer, Thomas Härtung, Dipak Kalra, Mihai G. Netea, Johan Neyts, Rino Rappuoli, Mariagrazia Pizza, Mélanie Saville, (unknown), Gerard D. Wright, Philippe Sansonetti, Michel Goldman	6
2	COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats 2023 ·BMJ Global Health ·Peter J. Hotez, Sarah C. Gilbert, Mélanie Saville, Lois Privor-Dumm, Salim S. Abdool Karim, (unknown), Jean‐Louis Excler, Jérôme H. Kim	7
3	Vaccine development for emerging infectious diseases breakdown → 2021 ·Nature Medicine ·Jean‐Louis Excler, Mélanie Saville, Seth Berkley, Jérôme H. Kim	256
4	Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12–13 February 2020 2021 ·Vaccine ·Gérald Voss, Jeanne‐Marie Jacquet, Nadia Tornieporth, Beate Kampmann, Ruth A. Karron, Ajoke Sobanjo-ter Meulen, Robert Chen, Marion F. Gruber, Nicole Lurie, (unknown), Jakob P. Cramer, Mélanie Saville, (unknown)	8
5	Developing vaccines against epidemic-prone emerging infectious diseases 2019 ·Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz ·Valentina Bernasconi, Paul A. Kristiansen, (unknown), Raúl Gómez Román, Alison A. Bettis, Solomon Abebe Yimer, Céline Gurry, Svein Rune Andersen, (unknown), (unknown), Arun Kumar, Johan Holst, Carolyn E. Clark, Jakob P. Cramer, John-Arne Røttingen, Richard Hatchett, Mélanie Saville, Gunnstein Norheim	26
6	Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases 2019 ·Vaccine ·Marcia A. Blackman, Mark A. Marchionni, (unknown), Matthew J. Hepburn, Bruce L. Innis, Alan D.T. Barrett, Kent E. Kester, John R. Mascola, James F. Cummings, Thomas P. Monath, M. Cristina Cassetti, Jérôme H. Kim, Mélanie Saville, Stephen J. Thomas	2
7	Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials 2016 ·PLoS neglected tropical diseases ·Anke Harenberg, (unknown), (unknown), Matthew Bonaparte, Florence Boudet, Mélanie Saville, Nicholas Jackson, Bruno Guy	15
8	Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward 2015 ·Vaccine ·Bruno Guy, Olivier Briand, Jean Lang, Mélanie Saville, Nicholas Jackson	120
9	Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia 2015 ·Vaccine ·Ilaria Dorigatti, Ricardo Aguás, Christl A. Donnelly, Bruno Guy, Laurent Coudeville, Nicholas Jackson, Mélanie Saville, Neil M. Ferguson	35
10	Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru 2012 ·Vaccine ·Claudio F. Lanata, (unknown), (unknown), (unknown), (unknown), Betzana Zambrano, Mélanie Saville, Denis Crevat	51
11	Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial breakdown → 2012 ·The Lancet ·Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, Kriengsak Limkittikul, Pornthep Chanthavanich, Saravudh Suvannadabba, (unknown), (unknown), Krisana Pengsaa, T. Anh Wartel, Annick Moureau, Mélanie Saville, Alain Bouckenooghe, Simonetta Viviani, Nadia Tornieporth, Jean Lang	636
12	Development of Sanofi Pasteur tetravalent dengue vaccine 2011 ·Americanae (AECID Library) ·Bruno Guy, Mélanie Saville, Jean Lang, João Bosco Siqueira, Lúcia Ferro Bricks	5
13	From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine 2011 ·Vaccine ·Bruno Guy, B. Barrère, (unknown), Mélanie Saville, R Teyssou, Jean Lang	240
14	Improving seasonal and pandemic influenza vaccines 2008 ·Influenza and Other Respiratory Viruses ·Mélanie Saville, Grenville Marsh, Agnès Hoffenbach	10
15	Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial 2008 ·The Journal of Infectious Diseases ·David J. Holland, Robert Booy, Ferdinandus de Looze, (unknown), (unknown), Jeff Karrasch, (unknown), Hatem H. Salem, Graham Mills, Jim Reid, Françoise Weber, Mélanie Saville	207
16	Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains 2007 ·Influenza and Other Respiratory Viruses ·Katja Höschler, Robin Gopal, Nick Andrews, Mélanie Saville, Stéphanie Pépin, John Wood, Maria Zambon	14
17	A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus Vaccine 2006 ·The Pediatric Infectious Disease Journal ·Timo Vesikari, Aino Karvonen, Tiina Korhonen, Kati Edelman, Raija Vainionpää, A. Salmi, Mélanie Saville, Iksung Cho, Ahmad Razmpour, Ruth Rappaport, Robert O’Neill, (unknown), William C. Gruber, Paul M. Mendelman, Bruce D. Forrest	83
18	Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care 2006 ·PEDIATRICS ·Timo Vesikari, Douglas Fleming, Javier Arı́stegui, André Vertruyen, Shai Ashkenazi, Ruth Rappaport, Jonathan R. Skinner, Mélanie Saville, William C. Gruber, Bruce D. Forrest	127
19	Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With Asthma 2006 ·The Pediatric Infectious Disease Journal ·Douglas Fleming, Pietro Crovari, Ulrich Wahn, Timo Klemola, Yechiel Schlesinger, (unknown), (unknown), María Luz García‐García, (unknown), (unknown), Ulrich Heininger, (unknown), Sheau‐Mei Cheng, Jonathan R. Skinner, Ahmad Razmpour, Mélanie Saville, William C. Gruber, Bruce D. Forrest	202
20	Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial 2006 ·The Lancet ·Jean-Louis Bresson, Christian Perronne, Odile Launay, (unknown), Mélanie Saville, John Wood, Katja Höschler, Maria Zambon	335

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact